Title : In silico and Experimental Evaluation of the Immunogenic Efficacy of a DNA-WT1 Vaccine in a Murine Model
Abstract:
This paper reports the development and expression of a DNA vaccine targeting WT1overexpressed in many solid and hematologic tumors. This vaccine incorporates immunogenic epitopes, guaranteeing broad demographic representation (99.26.26% worldwide and 98.37% in Mexico) via prominent HLA alleles such as A*02:01 and DRB1*04:071. Structural predictions revealed 86.21% of random coli, enhancing epitope accessibility and facilitating optimal antigen processing2. The construct also showed no expected allergenic or toxic repercussions fortifying its immunogenic potential. In vitro studies confirmed the vaccine’s capability in induce cytotoxic responses, particularly in WT1 expressing mouse models (4T1 and B16F10) 3–5. In vivo evaluations revealed that the non-adjuvant DNA-WT1 vaccine group demonstrated significantly superior prophylactic effectiveness and reduced tumor growth compared to their adjuvant counterparts, suggesting that incomplete Freund’s Adjuvant (IFA) might stifle T cells and the injection site, resulting in fatigue and apoptosis instead of robust anti-tumor responses as demonstrated previously9. Together, these insights underscore the vaccines capacity to provoke targeted cytotoxic T-cell responses unhindered by IFA-induced T-cell entrapment. Finally, these results suggest that the DNA-WT1 vaccines exhibited safety, immunogenicity, and the capacity to induce cytotoxic responses while limiting tumor development, making it a potential prophylactic vaccine.
